Mirum Pharmaceuticals, Inc.
$95.71
▼
-0.48%
2026-04-21 08:09:01
www.mirumpharma.com
NGM: MIRM
Explore Mirum Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5.78 B
Current Price
$95.71
52W High / Low
$109.28 / $38.22
Stock P/E
—
Book Value
$6.06
Dividend Yield
—
ROCE
-3.47%
ROE
-8.65%
Face Value
—
EPS
$-0.47
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
369
Beta
0.52
Debt / Equity
101.51
Current Ratio
2.67
Quick Ratio
2.55
Forward P/E
-876.85
Price / Sales
11.02
Enterprise Value
$5.68 B
EV / EBITDA
2,694.8
EV / Revenue
10.9
Rating
Strong Buy
Target Price
$125.36
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Verastem, Inc. | $6.52 | — | $557.75 M | — | -97.68% | -14.8% | $11.24 / $4.01 | $0.74 |
| 2. | uniQure N.V. | $18.04 | — | $1.07 B | — | -24.65% | -2.07% | $71.5 / $8.73 | $3.19 |
| 3. | Onconetix, Inc. | $0.73 | — | $0.51 M | — | -40.18% | -1.15% | $74.3 / $0.67 | $50.53 |
| 4. | Galmed Pharmaceuticals Ltd. | $0.75 | — | $4.81 M | — | -38.45% | -64.21% | $2.68 / $0.41 | $3.49 |
| 5. | Maze Therapeutics, Inc. | $26.84 | — | $1.4 B | — | -38.15% | -47.52% | $53.65 / $7.16 | $7.2 |
| 6. | Orchestra BioMed Holdings, Inc. | $4.35 | — | $268.03 M | — | -52.8% | -1.09% | $5.42 / $2.2 | $0.94 |
| 7. | Beam Therapeutics Inc. | $31.19 | — | $3.2 B | — | -27.72% | -8.11% | $36.44 / $15.35 | $12.48 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 148.93 M | 133.01 M | 127.78 M | 111.58 M | 99.41 M | — |
| Operating Profit | -4.57 M | 2.6 M | -4.99 M | -15.18 M | -24.22 M | — |
| Net Profit | -5.73 M | 2.9 M | -5.86 M | -14.68 M | -23.79 M | — |
| EPS in Rs | -0.09 | 0.05 | -0.1 | -0.24 | -0.39 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 521.31 M | 336.89 M | 186.37 M | 77.06 M |
| Operating Profit | -22.14 M | -87.61 M | -109.15 M | -131.22 M |
| Net Profit | -23.36 M | -87.94 M | -163.41 M | -135.66 M |
| EPS in Rs | -0.39 | -1.46 | -2.71 | -2.25 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 842.81 M | 670.75 M | 646.62 M | 352.91 M |
| Total Liabilities | 528.12 M | 445.11 M | 397.95 M | 210.87 M |
| Equity | 314.69 M | 225.64 M | 248.67 M | 142.04 M |
| Current Assets | 549.68 M | 392.79 M | 387.54 M | 190.22 M |
| Current Liabilities | 205.8 M | 126.55 M | 87.06 M | 64.73 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 55.83 M | 10.32 M | -70.94 M | -120.14 M |
| Investing CF | -23.95 M | -90.12 M | -107.2 M | 7.7 M |
| Financing CF | 40.14 M | 17.7 M | 336.6 M | 109.09 M |
| Free CF | 54.87 M | -10.67 M | -91.05 M | -120.41 M |
| Capex | -0.95 M | -20.99 M | -20.11 M | -0.28 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 80.76% | 141.85% | — | — |
| Earnings Growth % | 46.18% | -20.45% | — | — |
| Profit Margin % | -26.1% | -87.68% | -176.05% | — |
| Operating Margin % | -26% | -58.57% | -170.28% | — |
| Gross Margin % | 75.77% | 74.76% | 83.94% | — |
| EBITDA Margin % | -14.54% | -73.23% | -159.42% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.